Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 296

1.

A comparative study of primary and recurrent human glioblastoma multiforme using the small animal imaging and molecular expressive profiles.

Lin LT, Chiou SH, Lee TW, Liu RS, Hwang JJ, Chang CH, Ma HI, Lee YJ.

Mol Imaging Biol. 2013 Jun;15(3):262-72. doi: 10.1007/s11307-012-0591-x.

PMID:
22948536
2.

Identification of a novel set of genes reflecting different in vivo invasive patterns of human GBM cells.

Monticone M, Daga A, Candiani S, Romeo F, Mirisola V, Viaggi S, Melloni I, Pedemonte S, Zona G, Giaretti W, Pfeffer U, Castagnola P.

BMC Cancer. 2012 Aug 17;12:358. doi: 10.1186/1471-2407-12-358.

3.

Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway.

Nakano I, Joshi K, Visnyei K, Hu B, Watanabe M, Lam D, Wexler E, Saigusa K, Nakamura Y, Laks DR, Mischel PS, Viapiano M, Kornblum HI.

Neuro Oncol. 2011 Jun;13(6):622-34. doi: 10.1093/neuonc/nor023. Epub 2011 May 9.

4.
5.

Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.

Ashizawa T, Miyata H, Iizuka A, Komiyama M, Oshita C, Kume A, Nogami M, Yagoto M, Ito I, Oishi T, Watanabe R, Mitsuya K, Matsuno K, Furuya T, Okawara T, Otsuka M, Ogo N, Asai A, Nakasu Y, Yamaguchi K, Akiyama Y.

Int J Oncol. 2013 Jul;43(1):219-27. doi: 10.3892/ijo.2013.1916. Epub 2013 Apr 23.

PMID:
23612755
6.

Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.

Kuan CT, Wakiya K, Dowell JM, Herndon JE 2nd, Reardon DA, Graner MW, Riggins GJ, Wikstrand CJ, Bigner DD.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1970-82.

7.

Differential effects of low- and high-dose GW2974, a dual epidermal growth factor receptor and HER2 kinase inhibitor, on glioblastoma multiforme invasion.

Wang L, Liu Q, Zhao H, Cui K, Yao L, Nie F, Jin G, Hao A, Wong ST.

J Neurosci Res. 2013 Jan;91(1):128-37. doi: 10.1002/jnr.23140. Epub 2012 Nov 1.

PMID:
23115024
8.

Translational validation of personalized treatment strategy based on genetic characteristics of glioblastoma.

Oh YT, Cho HJ, Kim J, Lee JH, Rho K, Seo YJ, Choi YS, Jung HJ, Song HS, Kong DS, Seol HJ, Lee JI, Yoon Y, Kim S, Nam DH, Joo KM.

PLoS One. 2014 Aug 1;9(8):e103327. doi: 10.1371/journal.pone.0103327. eCollection 2014.

9.

STAT6 expression in glioblastoma promotes invasive growth.

Merk BC, Owens JL, Lopes MB, Silva CM, Hussaini IM.

BMC Cancer. 2011 May 20;11:184. doi: 10.1186/1471-2407-11-184.

10.

Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells.

Kim KH, Seol HJ, Kim EH, Rheey J, Jin HJ, Lee Y, Joo KM, Lee J, Nam DH.

Neuro Oncol. 2013 Feb;15(2):161-71. doi: 10.1093/neuonc/nos299. Epub 2012 Dec 20.

11.

The antitumor effects of Angelica sinensis on malignant brain tumors in vitro and in vivo.

Tsai NM, Lin SZ, Lee CC, Chen SP, Su HC, Chang WL, Harn HJ.

Clin Cancer Res. 2005 May 1;11(9):3475-84.

12.

Danthron inhibits the migration and invasion of human brain glioblastoma multiforme cells through the inhibition of mRNA expression of focal adhesion kinase, Rho kinases-1 and metalloproteinase-9.

Lin CC, Chen JT, Yang JS, Lu HF, Hsu SC, Tan TW, Lin YT, Ma YS, Ip SW, Wu JJ, Li YC, Chung JG.

Oncol Rep. 2009 Nov;22(5):1033-7.

PMID:
19787217
13.

Overexpression of alpha4 chain-containing laminins in human glial tumors identified by gene microarray analysis.

Ljubimova JY, Lakhter AJ, Loksh A, Yong WH, Riedinger MS, Miner JH, Sorokin LM, Ljubimov AV, Black KL.

Cancer Res. 2001 Jul 15;61(14):5601-10.

14.

Differential expression of MicroRNAs in patients with glioblastoma after concomitant chemoradiotherapy.

Park EC, Kim G, Jung J, Wang K, Lee S, Jeon SS, Lee ZW, Kim SI, Kim S, Oh YT, Shin JH, Jang HS, Choi BO, Kim GH.

OMICS. 2013 May;17(5):259-68. doi: 10.1089/omi.2012.0065. Epub 2013 Apr 15.

PMID:
23586679
15.

miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme.

Yin D, Ogawa S, Kawamata N, Leiter A, Ham M, Li D, Doan NB, Said JW, Black KL, Phillip Koeffler H.

Oncogene. 2013 Feb 28;32(9):1155-63. doi: 10.1038/onc.2012.132. Epub 2012 May 14.

16.

Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.

Onken J, Torka R, Korsing S, Radke J, Krementeskaia I, Nieminen M, Bai X, Ullrich A, Heppner F, Vajkoczy P.

Oncotarget. 2016 Mar 1;7(9):9876-89. doi: 10.18632/oncotarget.7130.

17.

HIF1-positive and HIF1-negative glioblastoma cells compete in vitro but cooperate in tumor growth in vivo.

Fiorenzo P, Mongiardi MP, Dimitri D, Cozzolino M, Ferri A, Montano N, Trevisi G, Maira G, Battistini L, Falchetti ML, Levi A, Pallini R.

Int J Oncol. 2010 Apr;36(4):785-91.

PMID:
20198320
18.

Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma.

Crommentuijn MH, Maguire CA, Niers JM, Vandertop WP, Badr CE, Würdinger T, Tannous BA.

Mol Oncol. 2016 Apr;10(4):625-34. doi: 10.1016/j.molonc.2015.11.011. Epub 2015 Dec 11.

19.

Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.

Ning S, Knox SJ.

Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):197-203.

PMID:
15337556
20.

Supplemental Content

Support Center